B-cell–Targeted Therapy for the Fibrotic Complications of Systemic Sclerosis Robert WoodrickJohn Varga CLINICAL TRIAL REPORT 24 November 2010 Pages: 1 - 3
Biomarkers in the Management of Scleroderma: An Update Giuseppina AbignanoMaya BuchFrancesco Del Galdo ReviewPaper 03 November 2010 Pages: 4 - 12
Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: From Animal Models to Clinical Trials Naoki IwamotoJörg H. W. DistlerOliver Distler ReviewPaper 02 November 2010 Pages: 21 - 27
A Unifying Hypothesis for Scleroderma: Identifying a Target Cell for Scleroderma William M. Mahoney JrJo Nadine FlemingStephen M. Schwartz ReviewPaper 23 December 2010 Pages: 28 - 36
The Scleroderma Kidney: Progress in Risk Factors, Therapy, and Prevention Guillaume BussoneAlice BéreznéLuc Mouthon ReviewPaper 09 November 2010 Pages: 37 - 43
Biomarkers of Scleroderma Lung Disease: Recent Progress Faye N. HantRichard M. Silver ReviewPaper 09 November 2010 Pages: 44 - 50
Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations Jessica GordonRobert Spiera ReviewPaper 18 November 2010 Pages: 51 - 58
Primary Thrombosis Prophylaxis in Antiphospholipid Antibody–Positive Patients: Where Do We Stand? Medha BarbhaiyaDoruk Erkan ReviewPaper 23 November 2010 Pages: 59 - 69
Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I Bas de LaatPhilip G. de Groot ReviewPaper Open access 03 November 2010 Pages: 70 - 76
Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients Michelle Petri ReviewPaper 27 October 2010 Pages: 77 - 80
Is Testing for Antiphosphatidylethanolamine Antibodies Clinically Useful? Marielle Sanmarco ReviewPaper 09 November 2010 Pages: 81 - 85
Update on Antiphospholipid Syndrome in Children Barry L. Myones ReviewPaper 16 November 2010 Pages: 86 - 89
New Insights into the Biology and Pathobiology of Beta2-Glycoprotein I Bill GiannakopoulosPeyman MirarabshahiSteven A. Krilis ReviewPaper 19 November 2010 Pages: 90 - 95